Related Experiment Video

Updated: Apr 21, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

11.9K

Selectivity Mechanism of ATP-Competitive Inhibitors for PKB and PKA

Ke Wu1, Jingzhi Pang1, Dong Song1

  • 1State Key Laboratory of Microbial Metabolism, Department of Bioinformatics and Biostatistics, College of Life Sciences and Biotechnology, Shanghai Jiaotong University, 800 Dongchuan Road, Shanghai, 200240, China.

Chemical Biology & Drug Design
|November 8, 2014
PubMed

Insights

Selective PKB inhibitors show higher binding affinity to PKB than PKA due to distinct interactions. This research aids in designing targeted cancer therapies by understanding inhibitor selectivity mechanisms.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Pharmacology

Background:

  • Protein kinase B (PKB) is a key regulator in the PI3K pathway, often dysregulated in cancers.
  • Protein kinase A (PKA), highly homologous to PKB, plays a vital role in metabolic regulation.
  • Targeting PKB specifically is crucial for developing effective antitumor drugs.

Purpose of the Study:

  • To elucidate the selectivity mechanism of PKB inhibitors against PKA using computational methods.
  • To develop 3D-QSAR models for predicting the potency and selectivity of PKB inhibitors.
  • To guide the design of novel, selective PKB inhibitors for cancer therapy.

Main Methods:

  • Molecular dynamics simulations were employed to analyze inhibitor-protein interactions.
  • 3D-Quantitative Structure-Activity Relationship (3D-QSAR) models were constructed and validated.
  • Comparative analysis of inhibitor interactions with PKB and PKA was performed.

Main Results:

  • Selective PKB inhibitors form more hydrogen bonds and hydrophobic contacts with PKB than with PKA.
  • The inhibitor M128 demonstrated higher potency against PKB compared to PKA, consistent with simulation findings.
  • Validated 3D-QSAR models provide a quantitative basis for predicting inhibitor selectivity.

Conclusions:

  • Understanding the specific binding interactions is key to designing selective PKB inhibitors.
  • 3D-QSAR models can accelerate the discovery of potent and selective antitumor agents.
  • This study provides a framework for rational drug design targeting PKB.
Keywords:
3D-QSARmolecular dynamics simulationprotein kinase Aprotein kinase Bselectivity

More Related Videos

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.4K
Assaying Protein Kinase Activity with Radiolabeled ATP08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

19.6K

Related Concept Videos

Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.8K
ATP Synthase: Mechanism01:48

ATP Synthase: Mechanism

In animals, the mitochondrial F1F0 ATP synthase is the key protein that synthesizes ATP molecules through a complex catalytic mechanism. While the nuclear genome encodes the majority of ATP synthase subunits, the mitochondrial genome encodes some of the enzyme's most critical components. The formation of this multi-subunit enzyme is a complex multi-step process regulated at the level of transcription, translation, and assembly. Defects in one or more of these steps can result in decreased...
19.3K
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
7.0K
cAMP-dependent Protein Kinase Pathways01:25

cAMP-dependent Protein Kinase Pathways

Cyclic Adenosine Monophosphate (cAMP) is an essential second messenger that activates protein kinase A (PKA) and regulates various biological processes. A single epinephrine molecule binds to GPCR and activates several heterotrimeric G proteins, each stimulating multiple adenylyl cyclase, amplifying the signal, and synthesizing large numbers of cAMP molecules. Small changes in cAMP concentration affect PKA activity. The binding of four cAMP molecules induces a conformational change in PKA,...
9.5K
Enzyme Inhibition01:30

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
95.5K
Enzymes02:34

Enzymes

Inside living organisms, enzymes act as catalysts for many biochemical reactions involved in cellular metabolism. The role of enzymes is to reduce the activation energies of biochemical reactions by forming complexes with its substrates. The lowering of activation energies favor an increase in the rates of biochemical reactions.
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
97.7K